Results 121 to 130 of about 52,122 (312)

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025

Addiction, EarlyView.
Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts, John Strang, Caroline Copeland   +2 more
wiley   +1 more source

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

Addiction, EarlyView.
Abstract Background and aims Despite the well‐documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug‐free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams.
Amy Bagshaw, Suleyman Shah, India Olchefske, Louise M. Paterson, Mike J. Crawford, Anne Lingford‐Hughes   +5 more
wiley   +1 more source

Buprenorphine maintenance treatment and its outcome among opioid dependent pregnant women: A case series from India

Indian Journal of Psychiatry
Perinatal opioid use is the major public health concern worldwide due to its hazardous effect on the mother and the developing fetus. Opioid agonist maintenance treatment with buprenorphine or methadone has been the recommended treatment for opioid ...
Piyali Mandal, Rajkumar Sanahan, Yesh Chandra Singh, Atul Ambekar   +3 more
doaj   +1 more source

NOCICEPTIN/ORPHANIN FQ RECEPTOR LIGANDS: PHARMACOLOGICAL STUDIES

, 2009
The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. At cellular level N/OFQ inhibits cAMP accumulation and Ca2+ conductance and stimulates K+ currents.
Fischetti, Carmela, Carmela Fischetti (7591079)   +1 more
core  

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)

Substance Abuse Treatment, Prevention, and Policy
Background Across different types of oral Opioid Agonist Treatment for people with Opioid Use Disorder, receiving a dose that meets their needs is associated with better outcomes. Evidence also shows patients are more likely to receive an “adequate dose”
Scott Beaumont, Tianna Magel, Scott MacDonald, Scott Harrison, Martin Schechter, Eugenia Oviedo-Joekes   +5 more
doaj   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, EarlyView.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

Opioid agonist treatment for pharmaceutical opioid dependent people (Review)

, 2016
Background There are increasing concerns regarding pharmaceutical opioid harms including overdose and dependence, with an associated increase in treatment demand.
Linda Gowing (20229114), Suzanne Nielsen (9618626), Briony Larance (19587904), Nicholas Lintzeris (5237414), Louisa Degenhardt (20846), Chyanne Kehler (20229117)   +5 more
core  

Opioid Agonist Therapy: Medication Barriers and Predicting Successful Retention

, 2023
Canada is currently experiencing an opioid crisis of an unprecedented magnitude. Opioid agonist therapy (OAT) medications are the first-line intervention for opioid use disorder.

core  

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

Informed Consent To Opioid Agonist Maintenance Treatment: Recommended Ethical Guidelines

, 2008
BACKGROUND: Some bioethicists have questioned whether opioid addicted individuals are able to provide free and informed consent to opioid agonist maintenance treatment. Conflicting motives for providing such treatment (e.g.
Hall, Wayne, Carter, Adrian
core   +1 more source